$BBLG News

BBLG Efficiency Improves as Crucial Trials Advance

Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances

Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1

Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities

Bone Biologics Files Prospectus To Offer Up To 6.46M Shares Of Common Stock By Selling Stockholders

BBLG Secures Financing for Critical Trials

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1

Bone Biologics Announces Validated Shelf Life Extension Of Its rhNELL-1 Protein Product To 29 Months

BBLG In Good Shape as Critical Tests Underway

Bone Biologics Q1 EPS $(0.43) Beats $(0.54) Estimate

Watching Bone Biologics; Zacks Small-Cap Research Gives Stock $22.20/Share Price Valuation

BBLG Financials Show Company in Solid Shape

BBLG Approaching Crucial Stage

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

Bone Biologics Extends Shelf Life Of rhNELL‑1 To 24 Months, Meeting Forecasts